In contrast, binding of Natalizumab to the CD4+Foxp3+ subset of regulatory T cells was significantly lower compared to their CD4+Foxp3 negative counterparts, both in healthy donors and MS patients (Figure 1b). This evidence concerns the gene FOXP3 and myeloid sarcoma.